The 2026 LiBBY trial does not answer safety questions for people with mild cognitive impairment. LiBBY means Life's End Benefits of cannaBidiol and tetrahYdrocannabinol, tested as THC/CBD oil for agitation in advanced dementia.
The Alzheimer's Association reports it as a Phase 2 study first reported July 14, 2026 Alzheimer's Association trial summary. Mild cognitive impairment means early memory or thinking changes with daily independence largely intact. That group was not enrolled, so the trial gives no direct safety or benefit evidence for MCI.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who joined the trial?
- Which product and dose were tested?
- What happened with agitation and safety?
- Why do results not apply to MCI?
Who joined the trial?
According to NeurologyLive, the trial used a multicenter randomized double-blind placebo-controlled design NeurologyLive trial report. It enrolled 120 participants across 10 U.S. sites and followed agitation for 12 weeks with home or residence visits.
NeurologyLive reports participants averaged 80 years old with late-stage Alzheimer's or other dementia. All had clinically significant agitation meeting hospice, FAST or ADEPT thresholds. These thresholds mark end-of-life eligibility, not early memory change.
Which product and dose were tested?
The LiBBY Study official site identifies the product as T2:C100, with 2 mg THC plus 100 mg CBD per dose LiBBY Study results page. Staff gave it twice daily as a purified rapid-acting oil in digestible oil.
The LiBBY Study team states findings apply only to that specific combination, dose and supervised delivery system. They do not extend to dispensary or over-the-counter cannabis products.
What happened with agitation and safety?
According to NeurologyLive, CMAI agitation scores fell more with THC/CBD than placebo at week 2 NeurologyLive efficacy report. CMAI rates agitation behaviors, and separation lasted through week 12. According to NeurologyLive, overall adverse-event rates were similar at 46.7% with THC/CBD and 42.4% with placebo.
Serious events were higher with active treatment, 23.3% versus 11.9%, driven by serious infections. NeurologyLive reports deaths during 12 weeks were 13.1% with THC/CBD versus 5.1% with placebo in this end-of-life population. Investigators judged no serious events drug-related.
Why do results not apply to MCI?
The MIMS Hong Kong report notes the small, short, largely White hospice sample. It reports 84% were White and provides no direct efficacy or safety evidence for ambulatory people with MCI. Ambulatory means living in the community, not receiving hospice care.
Use these checks before considering any cannabis product for memory concerns. Talk with your regular clinician first, because MCI care focuses on safety, other causes and planning. Write down behavior changes, doses, other illnesses and questions before the visit. Bring your MCI details, full medication list and agitation examples to that visit.
- Confirm diagnosis: MCI, dementia stage, agitation cause and hospice status
- Do not swap trial oil for dispensary or over-the-counter products
- List sleep drugs, sedatives, alcohol and fall risks for review
- Ask about local support, safety checks and follow-up plans
You Might Also Like
- Safety Questions After the 2026 LiBBY Dementia Trial: What the Findings Mean for People With Mild Cognitive Impairment
- AAIC 2026 LiBBY THC-CBD Agitation Trial: What the Findings Mean for People With Mild Cognitive Impairment
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: Study Design and Evidence Limits for People With Mild Cognitive Impairment
